Global Radiotherapy Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

In this report, the Radiotherapy Market has been segmented by Technology, Therapy Type, Application, End User, and Geography.

Radiotherapy Market, Segmentation by Technology

The Radiotherapy Market has been segmented by Technology into External Beam Radiotherapy - Image-Guided Radiotherapy (IGRT), Intensity Modulated Radiotherapy (IMRT), Stereotactic Therapy and Particle Therapy, Internal Beam Radiotherapy/Brachytherapy - Low-Dose-Rate (LDR) Brachytherapy, High-Dose-Rate (HDR) Brachytherapy and Pulsed-Dose-Rate Brachytherapy, Systemic Radiotherapy - Intravenous Radiopharmaceuticals, Oral Radiopharmaceuticals and Instillation Radiopharmaceuticals.

External Beam Radiotherapy

External beam radiotherapy (EBRT) is the most widely adopted technology, accounting for approximately 70% of the global radiotherapy market. It includes advanced techniques such as Image-Guided Radiotherapy (IGRT), Intensity Modulated Radiotherapy (IMRT), Stereotactic Therapy, and Particle Therapy. These modalities deliver precise doses of radiation to targeted tumors, minimizing damage to surrounding healthy tissues. IMRT and IGRT are widely used in treating complex cancers, while stereotactic and particle therapies are gaining popularity for their superior accuracy and outcomes.

Internal Beam Radiotherapy/Brachytherapy

Internal beam radiotherapy, or brachytherapy, represents around 20% of the market and involves placing radioactive material inside or near the tumor. It is categorized into Low-Dose-Rate (LDR) Brachytherapy, High-Dose-Rate (HDR) Brachytherapy, and Pulsed-Dose-Rate Brachytherapy. This technique is commonly used for treating prostate, cervical, and breast cancers, offering a highly localized radiation effect with reduced systemic exposure.

Systemic Radiotherapy

Systemic radiotherapy accounts for about 10% of the market and involves administering radioactive substances through the bloodstream. Delivery routes include Intravenous Radiopharmaceuticals, Oral Radiopharmaceuticals, and Instillation Radiopharmaceuticals. This approach is primarily used for cancers that have spread throughout the body, such as thyroid cancer, bone metastases, and certain neuroendocrine tumors. The rise in targeted radiopharmaceutical development is expected to expand this segment significantly.

Radiotherapy Market, Segmentation by Therapy Type

The Radiotherapy Market has been segmented by Therapy Type into External Beam Radiation Therapy, Internal Beam Radiation Therapy, and Systemic Radiation Therapy.

External Beam Radiation Therapy

External Beam Radiation Therapy (EBRT) is the most dominant segment, accounting for approximately 70% of the global radiotherapy market. This therapy type involves directing high-energy X-rays or proton beams at the tumor from outside the body using linear accelerators. EBRT is favored for its non-invasive precision, particularly in advanced modalities like IMRT, IGRT, and stereotactic therapy, which allow accurate targeting while sparing healthy tissue.

Internal Beam Radiation Therapy

Internal Beam Radiation Therapy, or brachytherapy, contributes around 20% of the market. It involves placing a radioactive source inside or near the tumor, delivering highly localized radiation. This method is commonly used for treating gynecologic, prostate, and breast cancers. The ability to deliver high doses over a shorter period with minimal side effects supports its clinical value and continued use.

Systemic Radiation Therapy

Systemic Radiation Therapy holds about 10% of the radiotherapy market. This therapy involves administering radiopharmaceuticals orally, intravenously, or by instillation, allowing radioactive substances to travel throughout the body. It is particularly useful in treating metastatic cancers such as thyroid, bone, or neuroendocrine tumors. As targeted therapies continue to evolve, this segment is expected to grow in clinical importance.

Radiotherapy Market, Segmentation by Application

The Radiotherapy Market has been segmented by Application into Prostate Cancer, Breast Cancer, Lung Cancer, Head and Neck Cancer, Colorectal Cancer, Gynecological Cancer, Cervical Cancer and Others.

Prostate Cancer

Prostate cancer is one of the leading applications of radiotherapy, accounting for approximately 25% of the total market. Radiotherapy, including both external beam and brachytherapy, is widely used for localized and advanced stages of prostate malignancies. Its effectiveness in reducing tumor size and preventing recurrence makes it a cornerstone in prostate cancer management.

Breast Cancer

Breast cancer represents about 20% of the radiotherapy application segment. Adjuvant radiotherapy is frequently administered after lumpectomy or mastectomy to minimize the risk of recurrence. The growing incidence of early-stage breast cancer and advances in targeted radiation delivery are fueling demand in this segment.

Lung Cancer

Lung cancer applications make up nearly 15% of the market. Radiotherapy plays a critical role in both curative and palliative care for patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Techniques like stereotactic body radiotherapy (SBRT) have improved survival and reduced side effects for inoperable cases.

Head and Neck Cancer

Head and neck cancer accounts for approximately 10% of the market. Radiotherapy is commonly used in combination with surgery or chemotherapy for treating cancers of the oral cavity, pharynx, and larynx. Precision techniques like IMRT have significantly improved outcomes by sparing critical structures.

Colorectal Cancer

Colorectal cancer contributes about 8% to the radiotherapy market. It is typically used in the neoadjuvant setting for rectal cancer or for palliation in advanced cases. Improved imaging and dose modulation technologies are enhancing treatment accuracy and reducing gastrointestinal toxicity.

Gynecological Cancer

Gynecological cancers, including ovarian and endometrial cancer, represent roughly 7% of the market. Radiotherapy is used as both a primary and adjunct therapy, particularly in inoperable cases or to address local recurrences. The integration of brachytherapy in treatment protocols has proven effective.

Cervical Cancer

Cervical cancer accounts for nearly 5% of the radiotherapy market. External beam radiotherapy combined with brachytherapy is a standard treatment for locally advanced cases. Increased screening and early detection in emerging markets are contributing to rising demand in this segment.

Others

The 'Others' category, making up the remaining 10% of the market, includes radiotherapy applications in brain tumors, pancreatic cancer, bladder cancer, and more. Technological advancements in adaptive radiotherapy and real-time imaging are enabling better targeting of these challenging tumor sites.

Global Radiotherapy Market, Segmentation by End User

The Global Radiotherapy Market has been segmented by End User into Hospitals and Independent Radiotherapy Centers.

Hospitals

Hospitals represent the largest end-user segment in the global radiotherapy market, accounting for approximately 75% of the total share. Most comprehensive cancer centers and multispecialty hospitals are equipped with advanced radiotherapy infrastructure, including linear accelerators and imaging-guided systems. The preference for hospitals is driven by their ability to offer integrated care, multidisciplinary treatment planning, and access to experienced oncologists.

Independent Radiotherapy Centers

Independent radiotherapy centers account for around 25% of the market. These specialized facilities focus exclusively on providing radiation oncology services, often featuring state-of-the-art equipment and shorter wait times. Their growth is fueled by the increasing demand for outpatient cancer treatment and efforts to decentralize healthcare delivery, especially in urban and suburban regions.

Global Radiotherapy Market, Segmentation by Geography

In this report, the Global Radiotherapy Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Global Radiotherapy Market Share (%), by Geographical Region

North America

North America dominates the global radiotherapy market, holding approximately 40% of the total share. The region’s leadership is driven by the presence of advanced healthcare infrastructure, high cancer incidence rates, and early adoption of cutting-edge radiotherapy technologies. Key contributing countries include United States and Canada, where government and private investments support continuous innovation in oncology care.

Europe

Europe accounts for nearly 30% of the global market, supported by strong regulatory frameworks and an increasing number of specialized cancer treatment centers. Countries such as Germany, United Kingdom, France, Italy, and Spain have implemented wide access to image-guided and intensity-modulated radiotherapy, driving market expansion.

Asia Pacific

Asia Pacific is the fastest-growing region, contributing about 20% of the global radiotherapy market. Rapid improvements in healthcare infrastructure, rising cancer burden, and growing investments in public and private radiotherapy centers are accelerating growth. Leading countries include China, India, Japan, South Korea, and Australia.

Middle East and Africa

Middle East and Africa represent roughly 5% of the global market. While adoption is still emerging, regional governments are investing in cancer care initiatives and radiotherapy equipment to improve access. Key markets include Saudi Arabia, United Arab Emirates, South Africa, and Egypt, where demand is rising for affordable treatment options.

Latin America

Latin America accounts for around 5% of the global radiotherapy market. Growth is fueled by rising oncology awareness, improved healthcare policies, and increasing availability of publicly funded cancer treatment centers. Prominent countries include Brazil, Mexico, Argentina, and Chile.

This report provides an in depth analysis of various factors that impact the dynamics of Global Radiotherapy Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers

• Technological advancements
• Increasing cancer prevalence
• Growing adoption of radiotherapy devices

• Rising awareness about cancer treatment: The global radiotherapy market has been witnessing significant growth, largely attributed to the rising awareness about cancer treatment. With cancer incidence rates on the rise globally, there's a growing demand for effective and advanced treatment options, of which radiotherapy remains a cornerstone. As more individuals become aware of the benefits of radiotherapy in targeting and eradicating cancer cells, the market has experienced a surge in adoption.

  Advancements in technology have further propelled the growth of the radiotherapy market. Innovations such as intensity-modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), and proton therapy have enhanced treatment precision, reduced side effects, and expanded the scope of radiotherapy to treat various types and stages of cancer. This increased efficacy and reduced adverse effects have contributed to a positive perception of radiotherapy among both patients and healthcare providers, driving market growth.

  Government initiatives and healthcare policies aimed at promoting cancer awareness and improving access to treatment have played a crucial role in expanding the radiotherapy market. Public health campaigns, funding for research and development, and reimbursement policies for radiotherapy procedures have all contributed to increasing the accessibility of radiotherapy services, particularly in developing regions where the burden of cancer is significant. As a result, the rising awareness about cancer treatment, coupled with technological advancements and supportive healthcare policies, is expected to continue driving the growth of the global radiotherapy market in the foreseeable future.

Restraints

• High treatment costs
• Side effects of radiotherapy
• Limited access in developing countries

• Stringent regulatory requirements: The global radiotherapy market is subject to stringent regulatory requirements that shape the landscape of this critical healthcare sector. Radiotherapy, a cornerstone of cancer treatment, involves the use of ionizing radiation to eliminate cancerous cells or inhibit their growth. Given the potential risks and complexities associated with radiation therapy, regulatory bodies worldwide impose stringent guidelines to ensure patient safety, treatment efficacy, and the reliability of equipment and procedures.

  One primary area of regulatory focus is the approval and clearance process for radiotherapy devices and technologies. Regulatory agencies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others assess the safety and effectiveness of new radiotherapy equipment and treatment techniques before they can be marketed and used in clinical settings. This rigorous evaluation process involves preclinical studies, clinical trials, and extensive documentation to demonstrate the device's performance and its potential benefits compared to existing treatments.

  Regulatory requirements extend to the operational aspects of radiotherapy facilities and the qualifications of healthcare professionals involved in delivering radiation therapy. Standards for facility design, radiation safety protocols, quality assurance programs, and personnel training are established to minimize the risk of errors, ensure treatment accuracy, and safeguard both patients and healthcare workers. Compliance with these regulations is essential for obtaining licensure to operate a radiotherapy center and for maintaining accreditation from relevant regulatory bodies and professional associations.

Opportunities

• Emerging markets expansion
• Advancements in personalized radiotherapy
• Integration of AI in radiotherapy

• Rising investment in healthcare infrastructure: The global radiotherapy market has witnessed significant growth in recent years, largely propelled by rising investments in healthcare infrastructure worldwide. As nations prioritize enhancing their healthcare systems to meet the growing demand for advanced medical treatments, radiotherapy has emerged as a crucial component in the fight against cancer. With an aging population and increasing prevalence of cancer cases globally, governments and private entities are allocating substantial funds towards bolstering radiotherapy facilities, equipment, and research.

  One of the primary drivers behind the increased investment in healthcare infrastructure is the growing awareness of the efficacy of radiotherapy in cancer treatment. As medical professionals and patients alike recognize the benefits of radiotherapy in targeting and destroying cancer cells, there is a growing demand for modernized radiotherapy technologies and facilities. Consequently, healthcare providers are expanding their radiotherapy departments and upgrading existing equipment to offer cutting-edge treatments, such as intensity-modulated radiation therapy (IMRT) and image-guided radiation therapy (IGRT), which improve treatment precision and minimize damage to surrounding healthy tissue.

  Technological advancements and innovation in radiotherapy techniques are further fueling investment in healthcare infrastructure. Researchers and medical device companies are continually developing new radiation delivery systems, software solutions, and imaging technologies to enhance treatment outcomes and patient experience. This relentless pursuit of innovation, coupled with supportive government policies and funding initiatives, is driving the expansion and modernization of radiotherapy infrastructure on a global scale. As a result, the radiotherapy market is poised for continued growth, with investments in healthcare infrastructure playing a pivotal role in shaping its trajectory.

Key players in Global Radiotherapy Market include:

• Varian Medical Systems
• Elekta AB
• Accuray Incorporated
• Siemens Healthineers
• ViewRay Inc
• IBA Dosimetry
• Eckert & Ziegler BEBIG
• Theragenics Corporation
• Hitachi Ltd
• Shinva Medical Instrument Co., Ltd

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis